Podcast: The UK's New Biosimilars Licensing Pathway
We Discuss The New MHRA Process And Its Global Significance For Biosimilars
In this podcast discussion, Generics Bulletin editor David Wallace talks to Duncan Emerton, director of Custom Intelligence and Analytics for Informa Pharma Intelligence, about the UK's new licensing procedure for biosimilars.
This month, the UK Medicines & Healthcare products Regulatory Agency released for public consultation its new licensing pathway for biosimilars that is set to apply from the start of 2021. (Also see "UK Lays Out Reduced-Data Pathway For Biosimilars" - Generics Bulletin, 9 Oct, 2020.)
In this podcast, Generics Bulletin editor David Wallace talks about the new pathway and its significance for the global biosimilars industry with Duncan Emerton, director of Custom Intelligence and Analytics for Informa Pharma Intelligence.